There are currently 121 clinical trials in Pasadena, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Keck Medical Center of USC Pasadena, Huntington Memorial Hospital, California Liver Research Institute and Lotus Clinical Research, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter Phase 1/3 study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended dose (RD) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a do... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: The Oncology Institute of Hope & Innovation, Pasadena, California
Conditions: Myelofibrosis
Register for Updates
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
NCT03041688
Recruiting
This phase Ib trial studies the side effects and best dose of navtemadlin when given together with decitabine and venetoclax in treating patients with acute myeloid leukemia that has come back after a period of improvement (recurrent), does not respond to treatment (refractory), or is newly diagnosed. Navtemadlin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2024
Locations: Keck Medical Center of USC Pasadena, Pasadena, California
Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
All
Ages:
50 years and above
Trial Updated:
05/31/2024
Locations: Payam Amini, Pasadena, California
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
Female
Ages:
Between 18 years and 60 years
Trial Updated:
05/31/2024
Locations: Huntington Memorial Hospital, Pasadena, California +1 locations
Conditions: Breast Cancer
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: California Eye Specialists Medical Group Inc, Pasadena, California
Conditions: Diabetic Macular Edema (DME)
Register for Updates
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
05/31/2024
Locations: Huntington Memorial Hospital, Pasadena, California
Conditions: Stage I Breast Cancer
Register for Updates
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: South California Heart Spc, Pasadena, California
Conditions: Heart Failure, Systemic Inflammation
Register for Updates
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) > 40% and ≤ 65%. Participants in both cohorts will be randomized into either low... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/29/2024
Locations: Southern California Heart Specialists, Pasadena, California
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
NCT05516498
Recruiting
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/29/2024
Locations: Research Site, Pasadena, California
Conditions: Liver Cirrhosis
Register for Updates
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03467958
Recruiting
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Havana Research Institute LLC, Pasadena, California
Conditions: Crohn Disease
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.
Gender:
All
Ages:
45 years and above
Trial Updated:
05/27/2024
Locations: California Liver Research Institute, Pasadena, California
Conditions: Overweight and Obesity
Register for Updates
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT06409130
Recruiting
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or "dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: California Liver Research Institute, Pasadena, California
Conditions: Alcohol-related Liver Disease
Register for Updates